Medicenna Therapeutics Corp

NASDAQ
MDNAF
paper.types.company
Rentabilité sur six mois: -35.49%
Rendement en dividendes: 0%

0.729 $

0 $ -0%
0.6 $
1.85 $

paper.min_max_per_year

Calendrier des promotions Medicenna Therapeutics Corp

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.

plus de détails
The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2001-08-27
ISIN
CA58490H1073
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
cad
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 20.96 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -91.64 0
ROE -146.88 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0 10
Debt/Ratio 0 10
Debt/Equity 2.69 5
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 0 0
Rentabilité EPS, % 40.65 6
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.729 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.772 $ 0 $ 0 $ -5.57 % 0 % 0 %
common.calendar.number_days.30d 0.839 $ 0.729 $ 0.823 $ -13.11 % 0 % 0 %
common.calendar.number_days.90d 0.711 $ 0.6 $ 0.867 $ 2.53 % 0 % 0 %
common.calendar.number_days.180d 1.13 $ 0.6 $ 1.29 $ -35.49 % 0 % 0 %
common.calendar.number_days.1y 1.74 $ 0.6 $ 1.85 $ -58.1 % 0 % 0 %
common.calendar.number_days.3y 1.11 $ 0.157 $ 2.07 $ -34.32 % 0 % 0 %
common.calendar.number_days.5y 2.59 $ 0.157 $ 5.97 $ -71.85 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.157 $ 5.97 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 1.18 $ 0.6 $ 1.12 $ -38.22 % 0 % 0 %

Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Fahar Merchant Ph.D. Founder, Chairman, President & CEO 1957 (68 années)
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder & Chief Development Officer 1957 (68 années)
Mr. David Hyman CA, CBV Chief Financial Officer 1973 (52 année)
Dr. Samuel R. Denmeade M.D. Scientific Advisor

Informations sur l'entreprise

Adresse: Canada, Toronto, 2 Bloor Street West - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.medicenna.com